Itraconazole - Mayne Pharma

Drug Profile

Itraconazole - Mayne Pharma

Alternative Names: Itragerm; Itraisdin; Lozanoc; Mytra; Subacap; SUBA™-itraconazole

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayne Pharma Group
  • Developer HedgePath Pharmaceuticals; Mayne Pharma Group
  • Class Antifungals; Antineoplastics; Azoles; Chlorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Mycoses

Highest Development Phases

  • Marketed Mycoses
  • Phase II Basal cell cancer

Most Recent Events

  • 30 Oct 2017 HedgePath Pharmaceuticals completes enrolment in the phase IIb SCORING trial in Basel cell cancer in USA (NCT02354261)
  • 09 Oct 2017 HedgePath Pharmaceuticals plans clinical trials for Lung cancer and Prostate cancer
  • 31 May 2017 Efficacy data from a phase IIb trial in Basal cell cancer released by HedgePath Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top